In vitro, CD19-ReTARGTPR induced potent and selective lysis across a range of CD19-expressing cancer cell lines, as well as primary CLL cells derived from patients, without provoking excessive cytokine release by T cells. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.